Following the reporting period, Prescient is delighted to report that the last patient enrolled to the Phase 1b study has experienced a complete response (complete eradication of disease). This patient is a 51- year-old woman with CTCL who had failed three prior therapies. This result further bolsters an already encouraging body of data from this study in a patient population characterised by unmet need and poor outcomes.
Thats the crux of it. Great signs
PTX Price at posting:
4.2¢ Sentiment: Buy Disclosure: Held
